Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Primary bone lymphoma: evaluation of chemoimmunotherapy as front-line treatment in 21 patients.

Pellegrini C, Gandolfi L, Quirini F, Ruggieri P, Stefoni V, Derenzini E, Broccoli A, Argnani L, Pileri S, Mercuri M, Baccarani M, Zinzani PL.

Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):321-5. doi: 10.1016/j.clml.2011.03.021. Epub 2011 May 7.

PMID:
21816370
2.

Prognostic factors and treatment efficacy in patients with primary diffuse large B-cell lymphoma of the bone: single institute experience over 11 years.

Liu YC, Gau JP, Yu YB, Hong YC, Yen CC, Liu CY, Chao TC, Hsiao LT, Liu JH, Chiou TJ, Tzeng CH.

Intern Med. 2014;53(2):95-101. Epub 2012 Mar 1.

3.

Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.

Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z, Wang X, Jiang K, Nastoupil LJ, Khan MK.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):569-77. doi: 10.1016/j.ijrobp.2013.02.007. Epub 2013 Mar 26.

PMID:
23540349
4.

Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.

Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, Salvi F, Rossi A, Broccoli A, Martelli M.

Clin Lymphoma Myeloma. 2009 Oct;9(5):381-5. doi: 10.3816/CLM.2009.n.074.

PMID:
19858058
5.

Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.

Mappa S, Marturano E, Licata G, Frezzato M, Frungillo N, Ilariucci F, Stelitano C, Ferrari A, Sorarù M, Vianello F, Baldini L, Proserpio I, Foppoli M, Assanelli A, Reni M, Caligaris-Cappio F, Ferreri AJ.

Hematol Oncol. 2013 Sep;31(3):143-50. doi: 10.1002/hon.2037. Epub 2012 Nov 14.

PMID:
23161567
6.
7.

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial (MInT) Group.

Lancet Oncol. 2011 Oct;12(11):1013-22. doi: 10.1016/S1470-2045(11)70235-2. Epub 2011 Sep 21.

PMID:
21940214
8.

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.

Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, Wang C, Zou S, Li J, Shen Z.

Ann Hematol. 2012 Jun;91(6):837-45. doi: 10.1007/s00277-011-1375-0. Epub 2011 Dec 9.

PMID:
22160255
9.

Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.

Redondo AM, Pomares H, Vidal MJ, Pascual MJ, Quereda B, Sancho JM, Polo M, López J, Conde E, Jarque I, Alonso N, Ramírez MJ, Fernández P, Sayas MJ, Requena MJ, Salar A, González JD, González-Barca E, Arranz R, Caballero D, Martín A.

Br J Haematol. 2014 Mar;164(5):668-74. doi: 10.1111/bjh.12676. Epub 2013 Nov 26.

PMID:
24274082
10.

[Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].

Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.

Ai Zheng. 2006 Apr;25(4):486-9. Chinese.

PMID:
16613686
11.

R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma.

Tomita N, Takasaki H, Miyashita K, Fujisawa S, Ogusa E, Matsuura S, Kishimoto K, Numata A, Fujita A, Ohshima R, Kuwabara H, Hagihara M, Hashimoto C, Takemura S, Koharazawa H, Yamazaki E, Fujimaki K, Taguchi J, Sakai R, Ishigatsubo Y.

Br J Haematol. 2013 May;161(3):383-8. doi: 10.1111/bjh.12281. Epub 2013 Feb 25.

PMID:
23432318
12.

Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study.

Dilhuydy MS, Lamy T, Foussard C, Gressin R, Casassus P, Deconninck E, Le Maignan C, Damotte D, Milpied N; Groupe Ouest-Est des Leucémies et Autres Maladies du Sang (GOELAMS).

Biol Blood Marrow Transplant. 2010 May;16(5):672-7. doi: 10.1016/j.bbmt.2009.12.530. Epub 2010 Jan 4.

13.

Randomized clinical trial to assess the efficacy of radiotherapy in primary mediastinal large B-lymphoma.

Avilés A, Neri N, Fernández R, Huerta-Guzmán J, Nambo MJ.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1227-31. doi: 10.1016/j.ijrobp.2011.09.012. Epub 2011 Dec 13. Retraction in: Zietman A, Avilés A. Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):286.

PMID:
22172907
14.

Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.

Papageorgiou SG, Diamantopoulos P, Levidou G, Angelopoulou MK, Economopoulou P, Efthimiou A, Constantinou N, Katsigiannis A, Korkolopoulou P, Pappa V, Economopoulou C, Georgiou G, Dimou M, Tsirigotis P, Kyrtsonis MC, Kotsianidis I, Kalpadakis C, Dimopoulos MA, Beris P, Meletis J, Pangalis GA, Dervenoulas J, Panayiotidis P, Vassilakopoulos TP.

Hematol Oncol. 2013 Mar;31(1):10-7. doi: 10.1002/hon.2012. Epub 2012 May 18.

PMID:
22610484
15.

[Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].

Zou GR, Zhang YJ, Xie FY, Zheng W, Li HX, Xia YF, Lin TY, Lu TX.

Ai Zheng. 2006 Dec;25(12):1543-9. Chinese.

PMID:
17166383
16.

[Primary breast lymphoma--a report of 27 cases with literature review].

Cao YB, Wang SS, Huang HQ, Xu GC, He YJ, Guan ZZ, Lin TY.

Ai Zheng. 2007 Jan;26(1):84-9. Review. Chinese.

PMID:
17222374
17.

Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.

Ohmachi K, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N, Takahashi N, Uike N, Eom HS, Chae YS, Terauchi T, Tateishi U, Tatsumi M, Kim WS, Tobinai K, Suh C, Ogura M.

J Clin Oncol. 2013 Jun 10;31(17):2103-9. doi: 10.1200/JCO.2012.46.5203. Epub 2013 May 6.

PMID:
23650408
18.

Early-stage primary bone lymphoma: a retrospective, multicenter Rare Cancer Network (RCN) Study.

Cai L, Stauder MC, Zhang YJ, Poortmans P, Li YX, Constantinou N, Thariat J, Kadish SP, Nguyen TD, Kirova YM, Ghadjar P, Weber DC, Bertran VT, Ozsahin M, Mirimanoff RO.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):284-91. doi: 10.1016/j.ijrobp.2011.06.1976. Epub 2011 Nov 11.

PMID:
22079728
19.

Survival of patients with transformed lymphoma in the rituximab era.

Guirguis HR, Cheung MC, Piliotis E, Spaner D, Berinstein NL, Imrie K, Zhang L, Buckstein R.

Ann Hematol. 2014 Jun;93(6):1007-14. doi: 10.1007/s00277-013-1991-y. Epub 2014 Jan 11.

PMID:
24414374
20.

The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.

Rambaldi A, Boschini C, Gritti G, Delaini F, Oldani E, Rossi A, Barbui AM, Caracciolo D, Ladetto M, Gueli A, De Crescenzo A, Passera R, Devizzi L, Patti C, Gianni AM, Tarella C.

Am J Hematol. 2013 Dec;88(12):1062-7. doi: 10.1002/ajh.23566. Epub 2013 Sep 30.

Supplemental Content

Support Center